Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase NA 6Phase 1 4Phase 4 1Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Small Cell Lung Carcinoma 11Pleural Effusion, Malignant 9Melanoma 7Ovarian Neoplasms 6NSCLC 6Pleural Effusion 5Neoplasms 5Head and Neck Neoplasms 5Stomach Neoplasms 4Mesothelioma 4Lung Diseases 4Carcinoma, Renal Cell 4Carcinoma 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Thoracic Neoplasms 3Pneumothorax 3Pleural Neoplasms 3Pancreatic Neoplasms 3Non-Squamous Non-Small Cell Lung Cancer 3Neoplasm Metastasis 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Venous Thromboembolism 2Urinary Bladder Neoplasms 2

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Meningeal Carcinomatosis × Thoracic × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡